Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors

被引:6
作者
Wong, Ka Kit [1 ]
Frey, Kirk A. [1 ]
Niedbala, Jeremy [1 ]
Kaza, Ravi K. [1 ]
Worden, Francis P. [2 ]
Fitzpatrick, Kellen J. [1 ]
Dewaraja, Yuni K. [1 ]
机构
[1] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Endocrine Oncol, Ann Arbor, MI 48109 USA
关键词
Ga-68-DOTATATE; Lu-177-DOTATATE; neuroendocrine tumor; PET/CT; peptide receptor radionuclide therapy; SPECT/CT; SUV; theranostics; RECEPTOR RADIONUCLIDE THERAPY; SST1-SST5; DOSIMETRY; SUBTYPES; PRRT;
D O I
10.1097/MNM.0000000000001592
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy Ga-68-DOTATATE PET to post-therapy Lu-177-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods PET/CT at similar to 60 min postinjection of Ga-68 DOTATATE and research Lu-177-SPECT/CT imaging similar to at 4h (SPECT1) and similar to 24h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)(mean) and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R-2 =0.19. 0.21, 0.29; PET versus SPECT2 R-2 =0.06, 0.16, 0.33 for TNRnliver,TNRspleen, TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P<0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver =3.5 [CI: 3.0-3.9], TNRspleen =1.3 [CI. 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 1.0 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4]. TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 1 6.9 [CI: 1 4-1 9.9], TNRspleen =3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on Lu-177 SPECT compared with Ga-68 PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs. (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:892 / 900
页数:9
相关论文
共 24 条
[1]   Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues [J].
Barone, R ;
Pauwels, S ;
De Camps, J ;
Krenning, EP ;
Kvols, LK ;
Smith, MC ;
Bouterfa, H ;
Devuyst, O ;
Jamar, F .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (09) :2275-2281
[2]   Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression [J].
Cherk, Martin H. ;
Kong, Grace ;
Hicks, Rodney J. ;
Hofman, Michael S. .
CANCER IMAGING, 2018, 18
[3]   Does the Pretherapeutic Tumor SUV in 68Ga DOTATOC PET Predict the Absorbed Dose of 177Lu Octreotate? [J].
Ezziddin, Samer ;
Lohmar, Jonas ;
Yong-Hing, Charlotte J. ;
Sabet, Amir ;
Ahmadzadehfar, Hojjat ;
Kukuk, Guido ;
Biersack, Hans-Juergen ;
Guhlke, Stefan ;
Reichmann, Karl .
CLINICAL NUCLEAR MEDICINE, 2012, 37 (06) :E141-E147
[4]   A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors [J].
Galne, Anni ;
Almquist, Helen ;
Almquist, Martin ;
Hindorf, Cecilia ;
Ohlsson, Tomas ;
Nordenstrom, Erik ;
Sundlov, Anna ;
Tragardh, Elin .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (12) :1717-1723
[5]  
Giesel FL, 2013, Q J NUCL MED MOL IM, V57, P171
[6]   PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma [J].
Haenscheid, Heribert ;
Sweeney, Reinhart A. ;
Flentje, Michael ;
Buck, Andreas K. ;
Loehr, Mario ;
Samnick, Samuel ;
Kreissl, Michael ;
Verburg, Frederik A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (08) :1284-1288
[7]  
Hans Vija P, CHARACTERISTICS XSPE
[8]   64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy [J].
Hicks, Rodney J. ;
Jackson, Price ;
Kong, Grace ;
Ware, Robert E. ;
Hofman, Michael S. ;
Pattison, David A. ;
Akhurst, Timothy A. ;
Drummond, Elizabeth ;
Roselt, Peter ;
Callahan, Jason ;
Price, Roger ;
Jeffery, Charmaine M. ;
Hong, Emily ;
Noonan, Wayne ;
Herschtal, Alan ;
Hicks, Lauren J. ;
Hedt, Amos ;
Harris, Matthew ;
Paterson, Brett M. ;
Donnelly, Paul S. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (06) :777-785
[9]   NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE [J].
Hope, Thomas A. ;
Abbott, Amanda ;
Colucci, Karen ;
Bushnell, David L. ;
Gardner, Linda ;
Graham, William S. ;
Lindsay, Sheila ;
Metz, David C. ;
Pryma, Daniel A. ;
Stabin, Michael G. ;
Strosberg, Jonathan R. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) :937-943
[10]   Discordant Uptake Between Diagnostic 68Ga-HA-DOTATATE PET/CT and Posttherapy 177Lu-HA-DOTATATE SPECT/CT in Patients With Neuroendocrine Tumors [J].
Huizing, Daphne M. V. ;
Aalbersberg, Else A. ;
van der Hiel, Bernies ;
Stokkel, Marcel P. M. ;
Versleijen, Michelle W. J. .
CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) :E475-E477